On September 6, 2023, Camac Partners, LLC and ATG Capital Management, LLC, the Group and its independent director candidates ? Michael Hacke and Chris McIntyre ? responded to misrepresentations and distortions included in Forte Biosciences, Inc?s recent presentation.

Camac Partners stated that Hacke and McIntyre have been nominated by the Group for election to the Company?s Board of Directors at the upcoming Annual Meeting of Stockholders currently scheduled for September 19, 2023. Camac Partners stated that as a reminder, the Group recently filed its own presentation that details why it believes the Company is in urgent need of boardroom change following years of poor performance and worst-in-class governance under Chairman and CEO Paul Wagner. In addition, the Group encourages stockholders to consider the facts before deciding which individuals to support at the upcoming Annual Meeting.